Earnings Feed
Start Free
Solid Biosciences Inc.·4

Feb 2, 8:15 PM ET

Hanrahan Jessie 4

Research Summary

AI-generated summary

Updated

Solid Biosciences (SLDB) Chief Regulatory Officer Jessie Hanrahan Sells Shares

What Happened
Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences (SLDB), sold 26,535 common shares in an open-market "sell-to-cover" transaction on Feb 2, 2026 for total proceeds of $170,803 (weighted average price $6.44). Those shares were sold to cover withholding taxes following the vesting/conversion of previously granted performance stock units (PSUs) and restricted stock units (RSUs). Earlier, Hanrahan had PSUs/RSUs convert or vest into common stock on Jan 29, 2026 (54,925 shares) and Jan 31, 2026 (27,625 shares), and the filing also reports new awards granted on Jan 29, 2026 (190,000 and 95,000 derivative awards).

Key Details

  • Transaction dates: PSU/RSU conversions on 2026-01-29 (54,925 shares) and 2026-01-31 (27,625 shares); open-market sale on 2026-02-02 (26,535 shares).
  • Sale price(s): weighted average $6.44; prices in the sale ranged from $6.295 to $6.580. Total reported proceeds: $170,803.
  • Awards/grants: two derivative awards reported on 2026-01-29 (190,000 and 95,000 units) that vest over time per the filing.
  • Footnotes of note: F3 — the Feb 2 sale was a sell-to-cover to satisfy tax withholding and was not a discretionary trade; F1 — PSUs convert one-for-one into common stock; F5 — the Jan 29 PSU vesting represented 25% of the PSU target due to certification of a performance milestone. Vesting schedules for the new grants/options are described in the filing (see F6–F8).
  • Shares owned after these transactions: not specified in the provided excerpt of the filing.
  • Timeliness: Form 4 was filed on Feb 2, 2026 and covers transactions dated Jan 29–Feb 2, 2026; the filing appears timely under the Form 4 reporting deadline.

Context
The derivative entries reflect vested/converting equity awards (PSUs/RSUs and an option grant), not open-market purchases. The sale was a routine sell-to-cover to pay withholding taxes after vesting (per the durable automatic sale instruction), so it does not represent a discretionary directional bet on the stock. For retail investors, outright purchases by insiders are generally considered stronger bullish signals than routine tax-covering sales.